What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
1. FDA shifts to advanced drug evaluation methods, reducing animal testing. 2. New Approach Methodologies (NAMs) emphasize AI and human models for testing. 3. Increased reliance on human-based models could lower drug development costs. 4. Certara (CERT) and Simulations Plus (SLP) could benefit from FDA's new guidelines. 5. Charles River Labs (CRL) faces revenue challenges due to reduced animal testing.